{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"title":"Delay for any reason"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}],"title":"Delay for Corneal AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Delay for Other Ocular Toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Delay for Hematologic Toxicity"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Delay for Physician/Patient Choice"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Delay for any other reason"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Number of participants for whom BLENREP dosing was delayed during treatment as categorized by reason.","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023.","id":"OG000","title":"Multiple Myeloma/Blenrep Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Treatment Characteristics: Dosing Patterns - Delays in Treatment With BLENREP Therapy","type":"PRIMARY","unitOfMeasure":"Participants"}